about
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myelomaClass III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerCombination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer modelPrognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantationFludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic CellsSuccessful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell TransplantationFatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma.Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironmentSarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells.The clonal origins of leukemic progression of myelodysplasia.Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.Immunotherapy for the treatment of multiple myeloma.Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression.A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis.Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma.Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma.The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen.Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype.STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (Kmm150).Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen.Decreased body mass index is associated with poor prognosis in patients with multiple myeloma.Rapidly progressing primary splenic angiosarcoma with fatal hemorrhagic event.Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era
P50
Q33419442-0ACB07A9-1EF3-4E02-8010-C237173962AFQ33426615-53B3EDDC-8E47-4256-ACD2-FB9318B555EEQ33434435-93F21AB4-0F33-4D5E-9040-64B2039BBA6DQ33562719-91494D8F-9D4E-4694-8079-6E6C1C8D74F1Q33589802-69B8C32E-F785-464C-A643-47DEE46C1BEEQ33689002-2CCBBD7C-56ED-47BA-903D-40CFA9529667Q34079559-72EF3242-9C09-4C95-AC7F-539439271251Q35152654-F866C901-4501-4095-91CB-9D09B5994FC5Q35524728-BDA04528-D027-48E3-A444-170501145450Q35843258-334B3064-6C93-4DE1-9158-66FD7868B21CQ35915790-50EB410F-A708-4565-933F-7C12C034E681Q36902204-5B410421-FA21-4D4E-939F-6B4B0C3DE1FDQ37010531-13DAB368-64D1-4A6C-8944-E969462B963FQ37223766-C1EF3CDE-9236-468F-9C9E-133AFFF03C54Q38406756-D9D11B22-E4B2-4E68-B07F-706243197D40Q38434694-2D1B1ED5-EF07-4A88-AEF0-4CF2886E4FF6Q38839102-048FCA30-B719-49CB-8F20-895192F97C41Q39161479-84487892-DEBE-4E8E-AAB4-A685F4E1D941Q40480218-0A647479-5C3C-478B-BC7E-BA1891979F6FQ41092396-65FF9C85-F51A-4C73-897C-83E630A127D9Q41233921-6F06BC13-D339-4E40-9749-4BBA57BE48EFQ41742650-2221FB00-22AA-4BCB-AC5C-C1C287E929FAQ42277364-C4D771F1-BB9A-4DB9-8AB8-1C55B7AF1039Q42336338-3C93B090-9654-42A3-9F8A-857EB1F0BFEAQ42371668-696E4D5F-C4DC-4559-8681-297DAE8935A6Q43473775-684998A1-44D2-456C-AC66-AAEC93CC84A2Q44003713-9A586E8B-804E-4559-AB8D-4A5542F725E0Q47105842-B22610E9-5B3D-4337-A0EA-6DBF0D089DB1Q47140962-32898887-4E9B-467B-BB3D-1FC2C10296C1Q48201389-E62C81C6-CF04-416B-A2B8-F84CD1F363B5Q48932698-7D0765A4-607D-439A-90F8-25A61703C724Q49433861-F06AFC0C-E5C3-425A-8D48-766AD6226A43Q49872904-A261552E-8B64-45C5-B986-C101B1B93421Q50021094-1204D261-1220-4B5F-A403-B5AF51C6506BQ51302317-0ABD4F17-CFCB-4F1D-ABD8-FEE3C7BB5D94Q51741922-54D0CF77-EEC3-4106-8067-52360031065AQ53350065-8AEC3065-74B2-4CCD-BCE2-150CF543C657Q54483269-B25A506D-978B-4E67-B8D9-0C2EC5D6FA28Q54729658-B677A9BC-8DEE-4885-9330-72B4E380D13CQ85651390-5C166A4D-7221-43AB-8DFA-F85BC368B78F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sung-Hoon Jung
@ast
Sung-Hoon Jung
@en
Sung-Hoon Jung
@es
Sung-Hoon Jung
@nl
Sung-Hoon Jung
@sl
type
label
Sung-Hoon Jung
@ast
Sung-Hoon Jung
@en
Sung-Hoon Jung
@es
Sung-Hoon Jung
@nl
Sung-Hoon Jung
@sl
prefLabel
Sung-Hoon Jung
@ast
Sung-Hoon Jung
@en
Sung-Hoon Jung
@es
Sung-Hoon Jung
@nl
Sung-Hoon Jung
@sl
P106
P1153
55511978300
P31
P496
0000-0003-3370-3987